Full Year 2023 Investor Presentation

32 Investor presentation Full year 2023 Novo NordiskⓇ Pipeline supports significant growth opportunities across all four strategic focus areas PHASE 1 NN1845 GSI NN1471 Pumpinsulin PHASE 2 NN9506 - GELA NN9440 INV-202 PHASE 3 NN1535 Icosema - SUBMITTED NN1436 APPROVED Insulin Icodec TresibaⓇ NN9924 - Oral Semaglutide 25 and 50 mg¹ INN7022 Nedosiran Xultophy NN7415 Concizumab in HwI, HA/HB2 LevemirⓇ SELECT Semaglutide 2.4 mg CVOT in obese population RyzodegⓇ NN9838 NN9932 Cagrisema NovoMixⓇ - NN9931 Oral Semaglutide 25 and 50 mg obesity Semaglutide 2.4 mg in MASH FiaspⓇ NovoRapidⓇ NN9041 - DNA Immunotherapy NN9505 GELA NN9542 - OW GLP-1/GIP co-agonist NN7533 - Ndec in SCD NN9904 OW oral sema - NN9650 OM GLP-1 /GIP NN9487 - Oral Amycretin NN9490 - Sc Amycretin NN6582 - LXR(a) in MASH NN6561 - VAP-1i in MASH NN6581 - MARC1 in MASH NN9003 - Stem Cells in HF NN7536 Etavopivat in Thalassemia NN7537 Evavopivat MDS NN9931 Gilead in MASH - NN9500 FGF-21 in MASH - NN9388 Cagrisema - NN9536 Semaglutide 7.2 mg - NN6535 Oral Semaglutide 14.0 mg in AD NN6019 Coarmitug in ATTR Cardiomyopathy NN6018 - Ziltivekimab in ASCVD NN9440 INV-202 in CKD NN6018 Ziltivekimab in HFPEF NN6023 - - Ocedurenone in CKD NN9001 - Stem Cells in PD NN6491 - Anti-ANGPTL3 in CVD NN7769 - Mim8 in HA NN7535 Etavopivat in SCD Other PHASE 3 trials SOUL - Oral semaglutide 14.0 mg CVOT FOCUS Semaglutide 1.0 mg in diabetic retinopathy FLOW Semaglutide 1.0 mg in CKD STRIDE Semaglutide 1.0 mg in PAD STEP Semaglutide 2.4 mg in HFPEF and T2D RybelsusⓇ OzempicⓇ3 Victoza Ⓡ WegovyⓇ SaxendaⓇ NovoSevenⓇ Novo Eight® EsperoctⓇ NovoThirteenⓇ Refixia® AlhemoⓇ4 RivflozaⓇ5 Diabetes care Obesity care Rare blood disorders Rare endocrine disorders Norditropin® Sogroya® Cardiovascular & Emerging Therapy Areas 1Submitted to EMA; 2Submitted to EU for HwI, to Japan for HA/HB; 3Higher doses of injectable semaglutide (8 mg and 16 mg) tested in phase 2; 4Approved in Canada (HAWI/HBWI), Australia (HAWI/HBWI), Switzerland (HAWI/HBWI) and Japan (HAWI/HBWI);5 Approved for PH1 by FDA. AATLD: Alpha-1 Antitrypsin Deficiency-associated Liver Disease; AD: Alzheimer's Disease; ANGPTL3: Angiopoietin-like protein 3; ASCVD: Atherosclerotic Cardiovascular Disease; ATTR: Transthyretin amyloidosis; CKD: chronic kidney disease; CVOT: Cardiovascular outcome trial; FGF-21: Fibroblast growth factor 21; GHD: Growth hormone disorder; GSI: Glucose Sensitive Insulin; HA: Haemophilia A; HF: Heart failure; HFPEF: heart failure with preserved ejection fraction; HwI: Haemophilia with inhibitors; JP: Japan; LXR(a): Liver X receptor alpha; MARC1: Mitochondrial amidoxime reducing component 1; MASH: Metabolic dysfunction-associated steatohepatitis; MDS: myelodysplastic syndrome; OM: Once monthly; OW: Once weekly; PAD: Peripheral arterial disease; PD: Parkinson's Disease; PH: Primary hyperoxaluria; SCD: Sickle cell disease; Sema: Semaglutide; US: United States; VAP-1i: Vascular adhesion protein-1 selective inhibitor

View entire presentation